PMID- 17371630
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20151119
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 169
IP  - 11
DP  - 2007 Mar 12
TI  - [Omalizumab (Xolair). Product description].
PG  - 993-5
AB  - Xolair, Omalizumab is a monoclonal antibody targeting the high-affinity receptor 
      binding site on human immunoglobulin E (IgE). Currently, omalizumab has been 
      approved for the treatment of persistent allergic asthma in patients who are 
      poorly controlled with inhaled corticosteroids. However, other allergic disorders 
      may be amenable to treatment with omalizumab because of its ability to inhibit 
      effector functions of IgE. Treatment with omalizumab should be administered by 
      specialists with training in diagnosis and treatment of allergic asthma. The 
      treatment should be withheld if no positive treatment effects are observed after 
      4 months.
FAU - Laursen, Lars Christian
AU  - Laursen LC
AD  - Herlev Hospital, Medicinsk Afdeling J 106. lclaursen@dadlnet.dk
LA  - dan
PT  - English Abstract
PT  - Journal Article
TT  - Omalizumab (Xolair). En produktbeskrivelse.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, IgE)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adult
MH  - *Anti-Allergic Agents/administration & dosage/pharmacokinetics/therapeutic use
MH  - *Anti-Asthmatic Agents/administration & dosage/pharmacokinetics/therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - *Antibodies, Monoclonal/administration & dosage/pharmacokinetics/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy
MH  - Child
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Omalizumab
MH  - Receptors, IgE/metabolism
MH  - Treatment Outcome
EDAT- 2007/03/21 09:00
MHDA- 2007/04/04 09:00
CRDT- 2007/03/21 09:00
PHST- 2007/03/21 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2007/03/21 09:00 [entrez]
AID - VP48343 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2007 Mar 12;169(11):993-5.